What Causes Irritability?
Discussion
Child abuse or non-accidental trauma is a clinical diagnosis. It is the constellation of history, physical examination, radiographic evaluation, laboratory testing and investigation that determines if child abuse has occurred. Irritability caused by fractures or other trauma can be a presenting symptom of abuse. Fractures can be a presentation but they are also common problems not associated with abuse. Femoral shaft fractures are estimated to account for only 1.6% of all fractures in children, therefore they are potentially more suspicious for child abuse. A review of femur fractures can be found here. A review...
Source: PediatricEducation.org - October 18, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
EMA Recommends VAXNEUVANCE Pneumococcal Vaccine for Approval EMA Recommends VAXNEUVANCE Pneumococcal Vaccine for Approval
The vaccine, which received FDA approval in July, protects against 15 strains of Streptococcus pneumoniae.International Approvals (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 15, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Alert Source Type: news
Allen West Goes on Unhinged Anti-Vaccine Tirade Amid COVID Hospitalization
The unvaccinated ex-congressman seemed to learn nothing from being sent to the emergency room with COVID-related pneumonia and low oxygen. (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2021 Category: Consumer Health News Source Type: news
Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults
RARITAN, N.J., October 2, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study results were presented as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2.“The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the severe ...
Source: Johnson and Johnson - October 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Pneumococcal vaccination reduces antibacterial failure and costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
RARITAN, N.J., September 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.The EVERGREEN study was initiated based on positive results from the Phase 2b CYPR...
Source: Johnson and Johnson - September 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Race against the virus: the Oxford AstraZeneca COVID-19 vaccine journey
In late December 2019, a cluster of unusual pneumonia cases - now known to be the first human cases of COVID-19 - were reported in Wuhan, China. Thanks to the quick action of an Oxford scientist and her team, work on the response to the new virus began. Members of the public have the opportunity to hear the story of the Oxford AstraZeneca COVID-19 vaccine at a free online event next month. (Source: University of Bristol news)
Source: University of Bristol news - September 28, 2021 Category: Universities & Medical Training Tags: Health, Public engagement; Institutes, Institutes, Elizabeth Blackwell, Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences, Faculty of Health Sciences, Translational Healt Source Type: news
New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.”
Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital.
The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the time of diagnos...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
The Gates Foundation ’s 2021 Report Shows That Childhood Vaccinations Dropped During the Pandemic—But There’s a Bright Side
This time last year, the Bill and Melinda Gates Foundation warned of a grim potential side effect from the COVID-19 pandemic: its disruptions to routine medical care could erase 25 years of progress on childhood vaccination, setting back global health by decades.
The 2021 installment of the foundation’s annual Goalkeepers report, which details progress on 18 metrics related to global health, equity and sustainability, contains some good news and some bad news. Childhood vaccination rates have suffered during the pandemic—but only about half as much as the Gates Foundation originally predicted, signaling that ma...
Source: TIME: Health - September 14, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 embargoed study healthscienceclimate Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Africa: Messenger RNA - How It Works in Nature and in Making Vaccines
[The Conversation Africa] Vaccines have long been an integral part of public health programmes around the world, reducing the spread and severity of infectious diseases. The success of immunisation strategies to protect children from diseases like polio, hepatitis B, and measles, and adults from influenza and pneumococcal disease, can be seen globally. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 7, 2021 Category: African Health Source Type: news
Adults need to take seriously vaccines for other diseases besides covid-19 and flu
Thousands of them get sick annually from illnesses — such as pertussis, shingles, human papillomavirus and pneumonia — that could have been prevented by vaccination. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - September 6, 2021 Category: Consumer Health News Authors: Marlene Cimons Source Type: news
15-Valent Pneumococcal Vaccine Shows Promise in Infants 15-Valent Pneumococcal Vaccine Shows Promise in Infants
In a recent study, the 15-valent pneumococcal conjugate vaccine Vaxneuvance was noninferior to the currently available 13-valent pneumococcal vaccine in healthy infants.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 3, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
